Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
Develops cancer drugs and injectable medicines for hospitals and patients in China.
2.40+0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-42.4%
The outlook
FDZB trades near its 52-week lows, sitting well below both its 50- and 200-day moving averages, indicating sustained weakness over recent months. The stock shows minimal analyst coverage, making consensus views difficult to assess. Current data reflects a bearish lean with the price near the lower end of its recent trading range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range8% of the way from its 52-week low to high
Market cap
$2.50B
52-wk high
4.67
52-wk low
2.20
50-day avg
2.41
200-day avg
2.87
Trailing P/E
—